Zepp Health Corporation Earnings Recaps
Q1 2026
Jun 10, 2026
Zepp Health’s shares plunged 28.8% following the quarter as investors were clearly disappointed by the company’s cautious outlook and signs of deceleration embedded in the commentary, outweighing reported revenue growth and margin expansion.
Key takeaways
- Amazfit branded revenue grew 33.8% year-over-year in Q1, driven by new premium product launches amid a seasonally soft quarter.
- The company highlighted a meaningful shift toward higher-priced premium models, with roughly 50% of T-Rex family sales at $399 and $549 tiers, lifting average selling price by over 20% year-over-year.
- Gross margins expanded despite inflationary pressures on memory and storage costs, attributed to improved product mix and cost discipline.
- Management emphasized a strategic pivot toward “hybrid training” positioning and deeper integration with HYROX, targeting serious athletes beyond casual users.
- However, the stock reaction suggests skepticism about the sustainability of growth, potential margin headwinds ahead, or tempered guidance alluded to in management’s commentary.
Q3 2025
Nov 5, 2025
Zepp Health Corporation reported robust third-quarter results, showcasing a 78.5% year-over-year revenue growth and a significant shift to operational cash inflow, demonstrating strong product demand and effective strategic execution.
Key takeaways
- Revenue soared 78.5% year-over-year, driven by successful product launches and strong brand recognition.
- Gross margin expanded from 36.2% to 38% due to effective mix management and ongoing margin improvement initiatives.
- Launched the Amazfit T-Rex 3 Pro, well-received by the outdoor community; recognized performance via athlete endorsement during high-profile events.
- Acquired Wild.AI, enhancing offerings in women's wellness and personalized coaching experiences.
- Continuous integration of Zepp OS enhancements improves user experience with AI-driven insights and expanded training capabilities.